Table 2: Comparison of epidemiological, clinical and treatment data in psoriatic arthritis patients with and without anxiety and correlation of anxiety with quality of life, depression, age, disease duration and activity indexes.
COMPARISON STUDIES |
||||
|
With anxiety N = 34 (62.9%) |
Without anxiety N = 20 (37.0%) |
P |
|
Females/Males |
18/16 |
9/11 |
0.57 |
|
Tobacco exposure |
20 (58.8%) |
7 (35%) |
0.09 |
|
Arthritis subset |
|
|
0.67 |
|
Polyarthritis |
11 (32.2%) |
3 (15%) |
|
|
Oligoarthritis |
18 (52.9%) |
12 (80%) |
|
|
Axial |
16 (47.0%) |
8 (40%) |
|
|
Distal interphalangeal |
3 (6.7%) |
2 (10%) |
|
|
Treatment |
||||
DMARDs (Methotrexate + leflunomide) |
22 (64.7%) |
12 (60%) |
0.72 |
|
Anti-TNF-alpha |
13 (38.2%) |
5 (25%) |
0.38
|
|
CORRELATION STUDIES OF BECK ANXIETY INVENTORY RESULTS: |
||||
|
Rho |
95% Confidence interval |
P |
|
Age |
0.05 |
-022 to +0.32 |
0.70 |
|
Arthritis duration |
-0.23 |
-0.48 to +0.04 |
0.09 |
|
Psoriasis duration |
-0.02 |
-0.30 to +0.25 |
0.85 |
|
PASI |
0.42 |
+0.16 to +0.62 |
0.001 |
|
ASDAS -ESR |
0.39 |
+0.13 to 0.60 |
0.003 |
|
ASDAS-CRP |
0.25 |
-0.02 to 0.49 |
0.06 |
|
CRP |
-0.04 |
-0.31 to +0.24 |
0.77 |
|
ESR |
0.22 |
-0.55 to +0.47 |
0.09 |
|
CES-D |
0.80 |
+0.68 to +0.88 |
< 0.0001 |
|
SF-12 (physical domain) |
-0.60 |
-0.75 to -0.39 |
< 0.0001 |
|
SF-12 (mental domain) |
-0.70 |
-0.82 to -0.53 |
< 0.0001 |
DMARDs: Disease Modifying Rheumatic Drugs; PASI: Psoriasis Area Severity Index; ASDAS: Ankylosing Spondylitis Disease Score; ESR: Erythrocyte Sedimentation Rate; CRP: C Reactive Protein; CES-D: Center for Epidemiological Studies Depression scale; SF-12: Short Form health survey with 12 questions